RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY OF GEFITINIB DOSE-ESCALATION (500MG/D VERSUS 250MG/D) IN ADVANCED NSCLC PATIENT ACHIEVED STABLE DISEASE (SD) AFTER ONE-MONTH GEFITINIB TREATMENT
JOURNAL OF THORACIC ONCOLOGY（2013）
关键词
dose-escalation,NSCLC,stable disease,gefitinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要